KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Operating Leases (2019 - 2025)

CRISPR Therapeutics AG's Operating Leases history spans 7 years, with the latest figure at $192.8 million for Q3 2025.

  • For Q3 2025, Operating Leases fell 8.49% year-over-year to $192.8 million; the TTM value through Sep 2025 reached $192.8 million, down 8.49%, while the annual FY2024 figure was $206.4 million, 7.44% down from the prior year.
  • Operating Leases for Q3 2025 was $192.8 million at CRISPR Therapeutics AG, down from $197.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $234.2 million in Q2 2022 and bottomed at $49.4 million in Q1 2021.
  • The 5-year median for Operating Leases is $214.9 million (2024), against an average of $205.2 million.
  • The largest annual shift saw Operating Leases soared 399.7% in 2021 before it dropped 8.49% in 2025.
  • A 5-year view of Operating Leases shows it stood at $212.9 million in 2021, then rose by 7.19% to $228.2 million in 2022, then decreased by 2.27% to $223.0 million in 2023, then decreased by 7.44% to $206.4 million in 2024, then fell by 6.61% to $192.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Operating Leases are $192.8 million (Q3 2025), $197.4 million (Q2 2025), and $201.9 million (Q1 2025).